Related Experiment Video
Updated: Jun 26, 2025
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.6K
Interleukine-10 in ovarian cancer
Gabriel Levin1, Walter Henry Gotlieb1
1Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
Chinese Clinical Oncology
|May 12, 2024
Summary
Interleukin-10 (IL-10) has a complex role in ovarian cancer (OC), influencing tumor growth and immune evasion. Understanding IL-10's function in the tumor microenvironment (TME) is crucial for developing effective OC therapies.
Area of Science:
- Immunology
- Cancer Biology
- Ovarian Cancer Research
Background:
- Interleukins, like Interleukin-10 (IL-10), are key signaling molecules in the tumor microenvironment (TME).
- IL-10 exhibits pleiotropic effects, potentially promoting cytotoxicity while also inhibiting anti-tumor immune responses.
- Ovarian cancer (OC) is a leading cause of gynecologic cancer deaths, characterized by a TME often unresponsive to immune checkpoint inhibition.
Purpose of the Study:
- To provide a comprehensive review of the current understanding of IL-10's role in ovarian cancer (OC).
- To highlight IL-10's influence on tumor growth, immune evasion, and therapeutic response in the OC TME.
- To consolidate existing, sometimes contrasting, research on IL-10 in OC basic science.
Main Methods:
- Literature review of basic science research on IL-10 in the OC TME.
- Analysis of studies spanning several decades to synthesize current knowledge.
- Focus on IL-10's signaling pathways and biological functions within the OC context.
Main Results:
- IL-10 plays a multifaceted role in OC progression, exhibiting both pro-tumor and anti-tumor effects.
- IL-10 contributes to immune modulation within the OC TME, impacting therapeutic efficacy.
- The complex nature of IL-10 suggests potential as both a therapeutic target and effector in OC treatment.
Conclusions:
- IL-10's intricate involvement in OC necessitates a thorough understanding for targeted therapeutic strategies.
- Further research into IL-10 signaling pathways is essential for overcoming OC treatment resistance.
- IL-10 represents a promising avenue for novel therapeutic interventions in ovarian cancer.
Related Concept Videos
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:27Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K